Menu Back toOpportunities for Harmonization of Clinical Trial Information in Regulatory Documents

DIA 2021 Global Annual Meeting

Opportunities for Harmonization of Clinical Trial Information in Regulatory Documents

Session Chair(s)

Robert  Paarlberg, MS

Robert Paarlberg, MS

  • Principal
  • Paarlberg & Associates LLC, United States
The global clinical trial transparency landscape has different requirements for disclosing clinical information. The COVID-19 pandemic has clearly illustrated the need for sponsors to expeditiously prepare clinical documents for submission to regulators under existing policies. This session will explore the challenges in submitting a more harmonized dossier to regulators and the public posting of clinical documents by regulators and opportunities for the future.
Learning Objective : Identify lessons learned from the recent COVID-19 experience and opportunities of harmonization in document submissions to regulators; Recognize the challenges to sponsors in preparing clinical documents for regulators in multiple regions; Discuss steps toward reaching a more harmonized approach.


Julie G. Holtzople

Industry Update

Julie G. Holtzople

  • Senior Director Clinical Transparency and Data Sharing
  • AstraZeneca, United States
Melissa  Jean

Health Canada Update

Melissa Jean

  • Scientific Reviewer, Public Release of Clinical Information
  • Health Canada, Canada
Radu  Popescu, MD

EMA Update

Radu Popescu, MD

  • Scientific Administrator
  • European Medicines Agency, Netherlands